tert-butyl (3R)-3-methyl-4-(2-pyridyl)piperazine-1-carboxylate | 1443748-50-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: tert-butyl (3R)-3-methyl-4-(2-pyridyl)piperazine-1-carboxylate
• 英文别名: tert-butyl (3R)-3-methyl-4-pyridin-2-ylpiperazine-1-carboxylate
• CAS: 1443748-50-2
• 化学式: C₁₅H₂₃N₃O₂
• 分子量: 277.367
• InChiKey: UOBLWUNWOVNTAJ-GFCCVEGCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  45.7
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (3R)-3-methyl-4-(2-pyridyl)piperazine-1-carboxylate 在 盐酸 、 N,N-二异丙基乙胺 作用下， 以 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 为溶剂， 生成 cyclohexyl-[(3R)-3-methyl-4-pyridin-2-ylpiperazin-1-yl]methanone
  参考文献：
  名称：

  N-Acyl-N′-arylpiperazines as negative allosteric modulators of mGlu1: Identification of VU0469650, a potent and selective tool compound with CNS exposure in rats

  摘要：

  Development of SAR in an N-acyl-N'-arylpiperazine series of negative allosteric modulators of mGlu(1) using a functional cell-based assay is described in this Letter. Characterization of selected compounds in protein binding assays was used to aid in selecting VU0469650 for further profiling in ancillary pharmacology assays and pharmacokinetic studies. VU0469650 demonstrated an excellent selectivity profile and good exposure in both plasma and brain samples following intraperitoneal dosing in rats. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.020
• 作为产物：
  描述：

  2-溴吡啶 、 (R)-4-Boc-2-甲基哌嗪 在 tris-(dibenzylideneacetone)dipalladium(0) 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 sodium t-butanolate 作用下， 以 1,4-二氧六环 为溶剂， 反应 0.17h， 生成 tert-butyl (3R)-3-methyl-4-(2-pyridyl)piperazine-1-carboxylate
  参考文献：
  名称：

  N-Acyl-N′-arylpiperazines as negative allosteric modulators of mGlu1: Identification of VU0469650, a potent and selective tool compound with CNS exposure in rats

  摘要：

  Development of SAR in an N-acyl-N'-arylpiperazine series of negative allosteric modulators of mGlu(1) using a functional cell-based assay is described in this Letter. Characterization of selected compounds in protein binding assays was used to aid in selecting VU0469650 for further profiling in ancillary pharmacology assays and pharmacokinetic studies. VU0469650 demonstrated an excellent selectivity profile and good exposure in both plasma and brain samples following intraperitoneal dosing in rats. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.05.020

文献信息

• PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF
  申请人：Navitor Pharmaceuticals, Inc.

  公开号：US20180127370A1

  公开（公告）日：2018-05-10

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用它们的方法。
• Phenyl amino piperidine mTORC inhibitors and uses thereof
  申请人：Navitor Pharmaceuticals, Inc.

  公开号：US10414727B2

  公开（公告）日：2019-09-17

  The present invention provides compounds, compositions thereof, and methods of using the same.

  本发明提供了化合物、其组合物以及使用方法。
• [EN] PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE LA PHÉNYL AMINO PIPÉRIDINE MTORC ET LEURS UTILISATIONS
  申请人：NAVITOR PHARM INC

  公开号：WO2018089499A1

  公开（公告）日：2018-05-17

  The present invention provides compounds, compositions thereof, and methods of using the same.